BridgeBio Oncology Therapeutics Inc. Common Stock (BBOT)
Stock · NASDAQ · Health Care
$2.82as of 10/16/2026
Price chart
Active signals
BBOT Signal Track Record
How signals performed across all stocks →What BBOT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 16 | -4.2% | 31% | September 9, 2026 |
| Bollinger Band Breakout | 11 | -3.5% | 0% | August 7, 2026 |
| Bollinger Band Breakdown | 10 | +1.5% | 60% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -0.2% | 50% | February 13, 2026 |
| Any 20-session window (baseline) | -0.5% | 44% |
Computed by MarketWall from daily closing prices since November 22, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BBOT
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 88
- Website
- bbotx.com/
Fundamentals
- 1-day range
- $3.82$4.1
- Market cap
- $703.34M
- P/E (trailing)
- —
- P/E (forward)
- -1.45
- EPS (trailing)
- $-3.04
- Dividend yield
- —
- Beta
- 0.68
- Avg. volume
- 451.6K
Forecasts
11 analyst ratings
BridgeBio Oncology Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
- EVOEvotec SE American Depositary Shares$1.38▼ 2.82%Market cap $693.72MP/E —$2.41$7.3
- GYREGyre Therapeutics Inc. Common Stock$6.08▼ 5.00%Market cap $713.53MP/E —$5.44$9.42
- OCSOculis Holding AG Ordinary shares$7.29▼ 1.49%Market cap $717.85MP/E —$7.11$34.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.38 | ▼ 2.82% | $2.41$7.3 |
| GYRE Gyre Therapeutics Inc. Common Stock | $713.53M | — | $6.08 | ▼ 5.00% | $5.44$9.42 |
| OCS Oculis Holding AG Ordinary shares | $717.85M | — | $7.29 | ▼ 1.49% | $7.11$34.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Beltran Pedro · July 1, 2026 · Tax Withholding1.0K @ $7.8
- Cobo Marc · July 1, 2026 · Tax Withholding125 @ $7.8
- Bihua Chen · July 1, 2026 · J130.9K
- Bihua Chen · July 1, 2026 · J1.70M
- Bihua Chen · July 1, 2026 · J2.69M
- Bihua Chen · July 1, 2026 · J4.53M
- Elmelech Idan · July 1, 2026 · Tax Withholding343 @ $7.8
- Yong Ben · July 1, 2026 · Tax Withholding1.0K @ $7.8
- Jake Bauer · June 16, 2026 · Grant31.7K
- Bihua Chen · June 16, 2026 · Grant31.7K
- Frank McCormick · June 16, 2026 · Grant31.7K
- Elmelech Idan · May 10, 2026 · Grant758.2K
- Beltran Pedro · May 10, 2026 · Grant1.10M
Institutional Ownership
March 31, 2026
- Total shares held
- 57.11M
- Total value held
- $506.79M
- Institutional holders
- 64
- Unknown17.88M
- Unknown4.89M
- Unknown3.29M
- Unknown2.82M
- Unknown2.82M
- Unknown2.82M
- Unknown2.63M
- Unknown2.53M
- Unknown2.19M
- Unknown2.09M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BBOT reports inducement grants under Nasdaq Rule 5635(c)(4)
BridgeBio Oncology Therapeutics announced that it has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The disclosure confirms the company’s compliance with regulatory reporting requirements for incentive arrangements. While the announcement does not provide details on the size of the grants, it highlights ongoing governance practices.
BBOT reports inducement grants under Nasdaq Rule 5635(c)(4). BridgeBio Oncology Therapeutics announced that it has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The disclosure confirms the company’s compliance with regulatory reporting requirements for incentive arrangements. While the announcement does not provide details on the size of the grants, it highlights ongoing governance practices.